Viro - viro - Ravimiamet

upjohn eesv - atorvastatiin - närimistablett - 20mg 30tk

Viro - viro - Ravimiamet

first pharma oÜ - atorvastatiin - õhukese polümeerikattega tablett - 10mg 200tk; 10mg 20tk; 10mg 30tk; 10mg 50tk; 10mg 14tk; 10mg 100tk; 10mg 90tk; 10mg 84tk; 10mg 28tk; 10mg 4tk

Viro - viro - Ravimiamet

first pharma oÜ - atorvastatiin - õhukese polümeerikattega tablett - 20mg 10tk; 20mg 90tk; 20mg 28tk; 20mg 4tk; 20mg 100tk; 20mg 14tk; 20mg 7tk; 20mg 50tk; 20mg 84tk; 20mg 500tk; 20mg 30tk; 20mg 20tk; 20mg 200tk

Viro - viro - Ravimiamet

first pharma oÜ - atorvastatiin - õhukese polümeerikattega tablett - 20mg 7tk; 20mg 200tk; 20mg 28tk; 20mg 4tk; 20mg 10tk; 20mg 100tk; 20mg 14tk; 20mg 90tk

Viro - viro - Ravimiamet

first pharma oÜ - atorvastatiin - õhukese polümeerikattega tablett - 10mg 4tk; 10mg 90tk; 10mg 10tk; 10mg 20tk; 10mg 50tk; 10mg 7tk; 10mg 98tk; 10mg 200tk; 10mg 84tk

Viro - viro - Ravimiamet

ideal trade links uab - atorvastatiin - õhukese polümeerikattega tablett - 40mg 10tk; 40mg 200tk; 40mg 20tk; 40mg 100tk

Euroopan unioni - viro - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ja immuunmoduleerivad ained, monoklonaalsed antikehad, - nivolumab bms on näidustatud lokaalselt levinud või metastaatilise lamerakulise mitteväikerakk-kopsuvähk (nsclc) ravimiseks täiskasvanutel eelneva kemoteraapia järgselt.

Euroopan unioni - viro - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antineoplastilised ained - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Viro - viro - Ravimiamet

sandoz pharmaceuticals d.d. - atorvastatiin - õhukese polümeerikattega tablett - 40mg 14tk; 40mg 30tk; 40mg 100tk; 40mg 250tk; 40mg 90tk; 40mg 63tk; 40mg 28tk; 40mg 91tk

Viro - viro - Ravimiamet

upjohn eesv - atorvastatiin - õhukese polümeerikattega tablett - 40mg 10tk; 40mg 30tk; 40mg 56tk; 40mg 14tk; 40mg 28tk; 40mg 7tk; 40mg 84tk; 40mg 200tk